Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206609 | 0.89 | TSHR (0.68) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL1937920 | 0.85 | TSHR (0.53) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL5379773 | 0.83 | TSHR (0.61) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL15689772 | 0.82 | TSHR (0.59) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL20123381 | 0.82 | TSHR (0.59) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL79996 | 0.81 | TSHR (0.63) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL20922038 | 0.81 | TSHR (0.53) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL23066881 | 0.80 | TSHR (0.49) | TSHRELANECETPSRCCA1 | |
| SCHEMBL218693 | 0.80 | TSHR (0.57) | TSHRELANECETPSRCIDO1 | |
| SCHEMBL2365443 | 0.80 | TSHR (0.57) | TSHRELANECETPSRCIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | claimed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | claimed |
| WO-2010136817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | WO | claimed |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | PAGET STEVEN D (US) | 2004-04-08 | — | — | US | claimed |
| US-6608081-B2 | Treating pneumonia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-19 | — | — | US | claimed |
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | claimed |
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | Lilac Therapeutics, Inc. | 2024-03-21 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4209483-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-114929676-A | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114072403-A | Prodrug compound | 百时美施贵宝公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11149043-B2 | Prodrug modulators of the integrated stress pathway | CALICO LIFE SCIENCES LLC (US) | 2021-10-19 | — | — | US | disclosed |
| WO-2021086874-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | GyanRx Sciences, Inc. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-1636182-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111193-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-6770664-B2 | PYRROLO(3,4-C)PYRAZOL-5(4H)-YL)-3-FLUOROPHENYL)-2-OXO-5 -OXAZOLIDINYL)METHYL)ACETAMIDE DERIVATIVES; BACTERICIDES AGAINST DRUG RESISTANT STAPHYLOCOCCUS, STREPTOCOCCUS, AND/OR ENTEROCOCCUS | PAGET STEVEN D (US) | 2004-08-03 | — | — | US | disclosed |
| US-6608081-B2 | Treating pneumonia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1301498-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002008213-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | OXA1L, NDUFS3, CYCS | TSHR 3826/4885ELANE 1980/4885CETP 4725/4885 |
| US-11149043-B2 | Prodrug modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | TSHR 2909/4885ELANE 3805/4885CETP 3494/4885 |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | OXA1L, NDUFS3, CYCS | TSHR 3826/4885ELANE 1980/4885CETP 4725/4885 |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | TSHR 3472/4885ELANE 198/4885CETP 3029/4885 |
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | UGDH, PGD, PNPO | TSHR 2776/4885ELANE 989/4885CETP 3827/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | TSHR 2776/4885ELANE 989/4885CETP 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.